Eton Pharmaceuticals Q3 2024 10-Q Filed

TL;DR

**Eton Pharma Q3 10-Q is IN! Check financials for latest performance.**

AI Summary

Eton Pharmaceuticals, Inc. filed its Q3 2024 10-Q report on November 12, 2024, for the period ending September 30, 2024. The company's financial statements show significant changes in its balance sheet, with total assets and liabilities reflecting the ongoing operations. Specific figures for revenue, net income, and cash flow are detailed within the report, providing insight into the company's financial performance during the third quarter.

Why It Matters

This filing provides investors and analysts with the latest financial performance data for Eton Pharmaceuticals, crucial for understanding the company's current financial health and future prospects.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Eton Pharmaceuticals is subject to regulatory risks, market competition, and the inherent uncertainties of drug development and commercialization.

Key Numbers

• 50,000,000 — Total Assets (Reported for the period ending September 30, 2024.)
• 25,836,204 — Total Liabilities (Reported for the period ending September 30, 2024.)
• 25,688,062 — Total Equity (Reported for the period ending September 30, 2024.)

Key Players & Entities

• Eton Pharmaceuticals, Inc. (company) — Filer of the 10-Q report
• 20240930 (date) — Conformed period of report
• 20241112 (date) — Filing date
• DEER PARK, IL (location) — Company's business and mailing address

FAQ

Key Financial Figures

• $0.001 — e on which registered Common stock, $0.001 par value per share ETON Nasdaq Glo

Filing Documents

• eton20240930_10q.htm (10-Q) — 922KB
• ex_744788.htm (EX-10.1) — 717KB
• ex_744790.htm (EX-10.2) — 126KB
• ex_716559.htm (EX-31.1) — 9KB
• ex_716560.htm (EX-31.2) — 9KB
• ex_716561.htm (EX-32.1) — 6KB
• 0001437749-24-034567.txt ( ) — 6223KB
• eton-20240930.xsd (EX-101.SCH) — 50KB
• eton-20240930_cal.xml (EX-101.CAL) — 36KB
• eton-20240930_def.xml (EX-101.DEF) — 416KB
• eton-20240930_lab.xml (EX-101.LAB) — 372KB
• eton-20240930_pre.xml (EX-101.PRE) — 438KB
• eton20240930_10q_htm.xml (XML) — 560KB

Financial Statements

Financial Statements 1 Condensed Balance Sheets as of September 30, 2024 (unaudited) and December 31, 2023 1 Unaudited Condensed Statements of Operations for the three and nine months ended September 30, 2024 and 2023 2 Unaudited Condensed Statements of Stockholders' Equity for the three and nine months ended September 30, 2024 and 2023 3 Unaudited Condensed Statements of Cash Flows for the nine months ended September 30, 2024 and 2023 5 Notes to Condensed Financial Statements 6 2

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 22 3

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 26 4

Controls and Procedures

Controls and Procedures 27 II OTHER INFORMATION 28 1

Legal Proceedings

Legal Proceedings 28 1A

Risk Factors

Risk Factors 28 2 Unregistered Sales of Equity Securities and Use of Proceeds 28 3 Defaults Upon Senior Securities 28 4 Mine Safety Disclosures 28 5 Other Information 28 6 Exhibits 28 Exhibit Index 29

Signatures

Signatures 30 i Table of Contents

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements Eton Pharmaceuticals, Inc. Condensed Balance Sheets (in thousands, except share and per share amounts) September 30, 2024 December 31, 2023 (Unaudited) Assets Current assets: Cash and cash equivalents $ 20,261 $ 21,388 Accounts receivable, net 5,591 3,411 Inventories 1,938 911 Prepaid expenses and other current assets 1,959 1,129 Total current assets 29,749 26,839 Property and equipment, net 33 58 Intangible assets, net 5,854 4,739 Operating lease right-of-use assets, net 193 92 Other long-term assets, net 12 12 Total assets $ 35,841 $ 31,740 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 2,684 $ 1,848 Debt, net of unamortized discount 4,125 5,380 Accrued Medicaid rebates 8,047 3,627 Other accrued liabilities 4,878 5,386 Total current liabilities 19,734 16,241 Operating lease liabilities, net of current portion 126 22 Total liabilities 19,860 16,263 Commitments and contingencies (Note 11) Stockholders' equity Common stock, $ 0.001 par value; 50,000,000 shares authorized; 25,836,204 and 25,688,062 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively 26 26 Additional paid-in capital 123,250 119,521 Accumulated deficit ( 107,295 ) ( 104,070 ) Total stockholders' equity 15,981 15,477 Total liabilities and stockholders' equity $ 35,841 $ 31,740 The accompanying notes are an integral part of these condensed financial statements. 1 Table of Contents Eton Pharmaceuticals, Inc. Condensed Statements of Operations (In thousands, except per share amounts) (Unaudited) For the three months ended For the nine months ended September 30, September 30, September 30, September 30, 2024 2023 2024 2023 Revenues: Licensing revenue $ 500 $ — $ 500 $ 5,500 Product sales and royalties 9,824 7,028 26,864 18,829 Total net revenues 10,324 7,028 27,364 24,329 Cost

View Full Filing

View this 10-Q filing on SEC EDGAR